Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Terminated
National Cancer Institute (NCI)
Phase 2
2015-02-01
This pilot trial studies how well sonidegib and buparlisib work in treating patients with
basal cell carcinoma that has spread to other places in the body. Sonidegib and buparlisib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Terminated
Novartis Pharmaceuticals
Phase 2
2015-02-01
This pilot trial studies how well sonidegib and buparlisib work in treating patients with
basal cell carcinoma that has spread to other places in the body. Sonidegib and buparlisib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma
Terminated
Anne Chang
Phase 2
2015-02-01
This pilot trial studies how well sonidegib and buparlisib work in treating patients with
basal cell carcinoma that has spread to other places in the body. Sonidegib and buparlisib
may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)
Recruiting
Senhwa Biosciences, Inc.
Phase 1
2019-04-01
This study is to determine the recommended phase II dose (RP2D) and schedule of CX-4945 when
administered orally twice daily for 28 consecutive days, in a 4-week (28 days) cycle, in
patients with locally advanced or metastatic basal cell carcinoma (BCC). The safety and
tolerability of CX-4945, preliminary evidence of antitumor effect, and the effect of CX-4945
treatment on the Hh signaling pathway will also be evaluated in this study.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
